{"_runtime":12.830806,"_step":0,"_wandb":{"runtime":12},"study_name":"Study from Banna 2022.pdf","extracted_data":{"countries":["United Kingdom","Switzerland"],"populations":[{"stage, histology":"IIIB/IVA, Adenocarcinoma","pdl1_status":"Negative","n":164},{"stage, histology":"IVB, Adenocarcinoma","pdl1_status":"Negative","n":113},{"n":51,"stage, histology":"IVB, Squamous","pdl1_status":"Negative"},{"pdl1_status":"Positive/High","n":151,"stage, histology":"IVB, Mixed"}],"results":{"pembrolizumab plus platinum-based chemotherapy":{"median_pfs":"8.0 months","os_12_month":"52.2%","group_difference":"Patients with high NLR (â‰¥4) had significantly shorter OS (median 11.8 vs 14.9 months, p=0.02) and PFS (median 6.6 vs 9.0 months, p=0.018) than those with low values.","median_os":"12.7 months"}},"study_name":"Study from Banna 2022.pdf","file_name":"Banna 2022.pdf","treatment_regimens":["pembrolizumab plus platinum-based chemotherapy"]},"status":"success","_timestamp":1.7426795663361878e+09}